Response to "Outcomes and costs associated with PHiD-CV, a new protein D conjugate pneumococcal vaccine, in four countries"

David Strutton; Sharon Hwang; Raymond Farkouh; Craig Roberts

doi:10.1016/j.vaccine.2011.02.103

Response to "Outcomes and costs associated with PHiD-CV, a new protein D conjugate pneumococcal vaccine, in four countries"

Vaccine. 2011 Oct 13;29(44):7589-90; author reply 7591-2. doi: 10.1016/j.vaccine.2011.02.103. Epub 2011 Mar 12.

Authors

David Strutton, Sharon Hwang, Raymond Farkouh, Craig Roberts

PMID: 21406264
DOI: 10.1016/j.vaccine.2011.02.103

Abstract

A recent supplement article by Talbird, Taylor, Knoll, Frostad, and García Martí reported estimates of public health impact and cost-effectiveness of the 10-valent pneumococcal conjugate vaccine compared with the 7-valent vaccine. Although the analysis applies a decision analytic model and modeling methodologies that are scientifically sound, many of the assumptions presented in the paper are inconsistent with the current evidence.

Publication types

Letter
Comment

MeSH terms

Female
Humans
Male
Pneumococcal Infections / epidemiology*
Pneumococcal Infections / prevention & control*
Pneumococcal Vaccines / economics*
Pneumococcal Vaccines / immunology*

Substances

Pneumococcal Vaccines